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Background: The identification of specific epitopes targeted by the host antibody response is important for
understanding the natural response to infection and for the development of epitope-based marker vaccines and
diagnostic tools for toxoplasmosis. In this study, Toxoplasma gondii GRA4 epitopes were identified using
software-based prediction and a synthetic peptide technique.
Methods: The complete GRA4 gene sequence was obtained from T. gondii of the Gansu Jingtai strain of
tachyzoites. The potential B cell epitopes of GRA4 was predicted using the PROTEAN subroutine in the DNASTAR
software package. The peptides with good hydrophilicity, high accessibility, high flexibility and strong antigenicity
were chemically synthesized and assessed by ELISA using pig sera from different time points after infection.
Results: The potential B cell epitopes of GRA4 predicted by bioinformatics tools focused on six regions of GRA4,
52–77 aa, 93–112 aa, 127–157 aa, 178–201 aa, 223–252 aa and 314–333 aa. Eleven shorter peptides from the six
regions were synthesized and assessed by ELISA using pig sera from different time points after infection. Three of
the eleven peptides (amino acids 62–77, 233–252 and 314–333) tested were recognized by all sera.
Conclusions: We precisely located the T. gondii GRA4 epitopes using pig sera collected at different time points
after infection. The identified epitopes may be useful for additional studies of epitope-based vaccines and
diagnostic reagents.
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Toxoplasma gondii is an obligate intracellular parasite that
infects a variety of mammals and birds, causing toxoplas-
mosis [1,2]. Toxoplasmosis is a zoonotic protozoan disease
that is distributed worldwide [3-5]. T. gondii is an import-
ant foodborne parasite that is primarily transmitted from
animals to humans through the consumption of infected
meat [6-12]. In some countries, pork is the most common
meat consumed, and several ethnic groups consume raw
pork [13]. Pigs are considered the primary source of human
infection with T. gondii [14,15]. Toxoplasmosis is a source
of significant economic loss for swine farmers because of
gross lesions in infected animals, which result in the carcass
being condemned at the time of slaughter, the expense* Correspondence: wangyh061001@163.com; yinhong@caas.net.cn;
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unless otherwise stated.associated with treatment, and weight loss associated
with clinical toxoplasmosis [16-19]. The development of
effective diagnostic reagents or vaccines is an important
goal because of the worldwide public health and economic
repercussions of T. gondii infection [20,21].
Attempts to develop a peptide-based vaccine for T. gondii
have been encouraging because they have demonstrated
significant protection in murine models [22-25]. Using
B cell epitopes for the serodiagnosis of toxoplasmosis
presents several advantages, such as precise knowledge
of the composition of the diagnostic antigen, the ability
to use more than one identified B cell epitope, and easy
standardization of the method [26]. The newly synthesized
multiepitope antigen is one of the most promising antigens
for the development of diagnostic kits for routine toxo-
plasmosis screening [27]. The identification of protein
epitopes will be useful for diagnostic purposes and for
the development of peptide vaccines [28-31]. The GRA
proteins, which are highly expressed by the parasite,td. This is an Open Access article distributed under the terms of the Creative
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chronic phases of infection and are of primary relevance to
host immunity. Studies demonstrated the ability of several
GRA antigens to confer protective immunity in mice in-
fected with T. gondii [32,33], in particular GRA4 [17,34-38].
Reports demonstrated that GRA4 might be used to design
novel and alternative diagnostic methods for toxoplasmosis
[39,40]. These results indicated that GRA4 is a promising
immunogenic candidate for the development of effective
diagnostic reagents or subunit vaccines that induce an
immunodominant response. For GRA4 epitopes, amino
acids 229–242 and 231–245 induce humoral and cellular
immune responses and these epitopes are defined as B and
T-cell epitopes [41,42]. The GRA4 231–245 peptide is
immunogenic and is considered a suitable alternative for
epitope-based vaccine design. Only a few GRA4 epitopes
have been defined.
With the development of bioinformatics, additional
methods have been developed or adapted from other
computational tools for the prediction of B cell epitopes.
We used five available methods based on the properties
of amino acids, Garnier–Robson [43] and Chou–Fasman
beta–turn prediction [44], Kyte–Doolittle hydrophilicity
prediction [45], Karplus–Schulz flexibility prediction
[46], Emini surface accessibility prediction [47], and
Jameson–Wolf antigenicity prediction [48], to study and
analyze the potential epitopes of SAG1 and GRA1
[29,30]. Using experimental verification, we found that
these five methods reliably predicted the results. All lin-
ear peptides from GRA4, which are recognized by the
humoral immune response in pigs, have not been previ-
ously examined systematically. The B cell epitopes of
GRA4 were analyzed using software-based prediction
and a synthetic peptide technique.
Methods
Serum samples
A total of 51 T. gondii-positive sera samples previously
collected from pigs experimentally infected with the Gansu
Jingtai strain (isolated from a pig with acute toxoplasmosis)
in our laboratory (The experimental protocol was approved
by the Ethical Committee of the Lanzhou Veterinary
Research Institute, Chinese Academy of Agricultural
Sciences) were evaluated in this study. Twelve pig serum
samples were collected at the time of presentation of clin-
ical symptoms (G1), 18 follow-up samples were collected
on days 14 to 35 after the onset of symptoms (G2) and 21
samples were collected on days 60 to 120 after the onset of
symptoms (G3). The presence of Toxoplasma IgM and IgG
antibodies was determined by T. gondii lysate antigen-
ELISA. The G1 and G2 samples were positive for IgM and
IgG against T. gondii. The G3 samples were positive for
IgG against T. gondii. Ten serum samples negative for
T. gondii IgM and IgG were used as controls.Amplification, cloning and sequencing of the GRA4 gene
To obtain the complete GRA4 gene sequence, a recombin-
ant plasmid encoding the GRA4 gene was constructed as
described below. T. gondii DNA was obtained from Gansu
Jingtai strain tachyzoites using the Universal Genomic DNA
Extraction kit (TaKaRa Biotechnology Co., Ltd, Dalian,
China), and the GRA4 sequence was amplified using the
primers 5′-GATACGTAATGCAGGGCACTTGGTTTT-3′
and 5′- CGGAATTCTCACTCTTTGCGCATTCTT -3′.
The PCR amplification was performed using the TaKaRa
TaqTM kit according to the manufacturer’s instructions.
The sample was subjected to an initial denaturation (94°C
for 5 min), 35 cycles of denaturation (94°C for 1 min),
annealing (60°C for 30 s) and elongation (72°C for 1 min),
and a final extension at 72°C for 10 min. The PCR-generated
fragment was purified and cloned into the pMD-18 T vector
(TaKaRa Biotechnology Co., Ltd, Dalian, China). The re-
combinant plasmid was used to transform Escherichia
coli JM 109 competent cells, and the recombinant cells were
selected on LB plates with ampicillin (100 mg/L), X-Gal (5-
bromo-4-chloro-3-indolyl-β-D-galactopyranoside; 70 mg/L)
and IPTG (isopropyl beta-D-thiogalactopyranoside; 80 μM)
at 37°C for 24 h (ampicillin, X-Gal and IPTG were from
TaKaRa Biotechnology Co., Ltd, Dalian, China). Positive
colonies were inoculated into LB liquid medium containing
ampicillin (100 mg/L) and incubated at 37°C for 16 h. The
recombinant plasmid was extracted using a Plasmid Purifi-
cation kit (TaKaRa Biotechnology Co., Ltd, Dalian, China).
The positive colonies identified by PCR were sequenced by
TaKaRa Biotechnology Co., Ltd (Dalian, China).
Prediction of the epitopes
To analyze the GRA4 B cell epitopes, the deduced amino
acid sequence of GRA4 was analyzed using the PROTEAN
subroutine in the DNASTAR software package. This sub-
routine uses the Garnier-Robson [43] and Chou-Fasman
[44] algorithms for predicting the alpha, beta, and turn
regions, the Garnier-Robson algorithm for predicting
the coil regions, the Kyte-Doolittle [45] algorithm for
predicting hydrophilicity, the Karplus-Schultz [46] algo-
rithm for predicting flexibility, the Emini [47] algorithm
for predicting surface probability and the Jameson-Wolf
[48] algorithm for predicting antigenicity. Based on this
analysis, the peptides with good hydrophilicity, high accessi-
bility, high flexibility and strong antigenicity were selected
as the antigen epitopes. These peptides were chemically
synthesized by GL Biochem Ltd (Shanghai, China). The
peptide sequences are shown in Table 1.
ELISA analysis
Enzyme-linked immunoassays specific for each peptide
were performed as described by Cardona et al. [49] with
minor modifications. The microplates were coated with
100 μl (10 μg/ml) of each peptide diluted in carbonate
Table 1 Sequences of synthesized peptides
Peptides Start and end position Sequence
P1 52–71 aa HSMYGNKTPYPYADGQQGSP
P2 62–77 aa PYADGQQGSPPPQGQL
P3 93–112 aa QGVPQAPQAAGGPGSPMNGG
P4 127–146 aa GTPGHPVQAIPQQPLRTQAT
P5 136–157 aa IPQQPLRTQATATYYHPAAAPP
P6 172–191 aa PGAEVTPGYSGLQLRQQSQY
P7 182–201 aa DYSYPGTTSTPTPPRPASYG
P8 192–211 aa GLQLRQQSQYDYSYPGTTST
P9 223–242 aa AFSDSVSVSTEDSGLTVVRD
P10 233–252 aa EDSGLTVVRDSSSSESTVTP
P11 314–333 aa TELDDGYRPPPFNPRPSPYA
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0.293 g/100 mL). The plates were incubated for 1 h at
37°C, then for 48 h at 4°C and 1 h at 37°C. Non-specific
ligand sites were blocked with 100 μl 2% casein phosphate
buffer for 1 h at 37°C. The plates were washed and incu-
bated with 100 μl serum diluted to 1:100 in 5% casein
phosphate buffer for 1 h at 40°C. After washing, 100 μl
rabbit anti-pig peroxidase-conjugated IgG (Sigma) diluted
to 1:4000 in 6% casein phosphate buffer was added for
20 min at 37°C. After the washes, the horseradish peroxid-
ase activity was detected using TMB for 30 min at 37°C
and stopped with a 5% H2SO4 solution. The absorbance of
duplicates for each serum sample was measured at 450 nm.
A positive cut-off point was determined by estimating the
mean average absorbance of ten negative controls plus two
standard deviations.
To determine the specificity of the anti-peptide anti-
body, an ELISA using irrelevant peptides from the BL21
of the orf virus previously synthesized by our laboratory
(sequence: VDVQSKDKDADELRE) was also performedFigure 1 The secondary structures, flexibility, hydrophilicity, surface pas described above. As controls, ELISAs using soluble
T. gondii antigen (STAg) and recombinant GRA4 from
the RH strain of T. gondii previously expressed by our
laboratory were also performed as described above,
with minor modifications. Briefly, non-specific ligand sites
were blocked with 100 μl 5% BSA phosphate buffer. Pig
sera were diluted 1:100 in PBS and used as the primary
antibody. The rabbit anti-pig peroxidase-conjugated IgG
diluted 1:8000 in PBS was used as the secondary antibody.
Results and discussion
Bioinformatics is important for predicting protein struc-
ture, function and biological characteristics. With the aid
of software and databases for the prediction of epitopes,
we can reduce the number of proteins of interest and sig-
nificantly decrease the number of laboratory experiments.
Bioinformatics has been widely used in the analysis of pro-
tein epitopes [50-54]. In the present study, the secondary
structure of GRA4 was predicted by the Garnier–Robson
and Chou–Fasman algorithms based on the sequence of
the GRA4 gene. A flexibility plot, hydrophilicity plot, sur-
face probability plot and antigenic index for GRA4 were
obtained using the Karplus–Schulz, Kyte–Doolittle, Emini
and Jameson–Wolf algorithms, respectively (Figure 1).
The variability, fragment mobility, and hydrophilicity
are important features of antigenic epitopes. The exist-
ence of flexible regions, such as coil and turn regions,
provides powerful evidence for epitope identification
[53,54]. Based on the results obtained with these methods,
potential B cell epitopes on GRA4 were predicted, includ-
ing 52–71 aa, 62–77 aa, 93–112 aa, 127–146 aa, 136–157
aa, 172–191 aa, 182–201 aa, 192–211 aa, 223–242 aa,
233–252 aa and 314–333 aa.
In the past, several experimental techniques were de-
veloped for mapping antibody interacting residues on
an antigen, including the identification of interactingrobability and antigenicity index for T. gondii GRA4.
Figure 2 ELISA of IgG antibodies against different peptides in the four groups of pig sera. (A), (B), (C), (D), (E), (F), (G) and (H) showing
the absorbances targeting P1, P3, P4, P5, P6, P7, P8, and P9, respectively. The cut-off point for the assay is indicated by the horizontal line.
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plexes [55,56]. One popular approach is the synthetic
peptide technique, which primarily identifies sequentialFigure 3 ELISA of IgG antibodies against different peptides in the fou
targeting P2, P10 and P11, respectively. The cut-off point for the assay is inepitopes [56]. Using this technique, we verified the validity
of the predicted epitopes in the present study. All eleven
of the predicted epitope peptides were evaluated by ELISAr groups of pig sera. (A), (B), (C) and (D) showing the absorbances
dicated by the horizontal line.
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P10 and P11 were recognized by all sera. The other eight
peptides were recognized by select sera from various time
points after infection (Figure 2; number of positive samples/
tested for each peptide as follows: P1:7/51, P3:36/51, P4:23/Figure 4 ELISA of IgG antibodies against an irrelevant peptide (A), ST
The cut-off point for the assay is indicated by the horizontal line.51, P5:12/51, P6:17/51, P7:27/51, P8:18/51 and P9:21/51).
The results of the ELISA for three peptides, P2, P10 and
P11, are shown in Figure 3. For each of the three peptides,
no significant differences were observed between the
mean absorbances of the three groups (G1, G2 and G3)Ag (B) and recombinant GRA4 (C) in the four groups of pig sera.
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differences were observed between the mean absorbances
of the three peptides, P2, P10 and P11. In our study, we
found that the three peptides derived from GRA4 were
recognized by pig sera from different time points after
infection. The reactivity of these epitopes does not
seem to be dependent upon the time of infection, sug-
gesting that the host response is constantly activated
by these protein fragments.
To determine the specificity of the anti-peptide antibody,
an ELISA using an irrelevant peptide was also performed.
This peptide did not react with the sera (Figure 4A). To
compare the serological reactivity of the peptides with
STAg and recombinant GRA4, ELISAs using STAg and
recombinant GRA4 were also performed. A total of 51 sera
samples reacted with STAg (Figure 4B) and recombinant
GRA4 (Figure 4C).
Many tools for identifying and predicting B cell epi-
topes have been developed previously [50,51,55,56].
Conformational epitope selection relies on the determin-
ation of the tertiary structure of an antigen to identify
residues that interact with antibodies. The experimental
techniques required to determine the tertiary structure
of the antigen, such as crystallography, are expensive
and time consuming, and the mapping of conformational
epitopes has been severely hampered. The majority of
methods and databases have focused on the identification
of linear epitopes [57,58]. In the present study, linear
epitopes were analyzed using software-based predic-
tions, and three of the eleven predicted epitope peptides
were confirmed by synthetic peptide techniques. The
use of a bioinformatics method in combination with a
molecular biology method is a useful method to screen
for linear epitopes.Conclusion
Using peptide synthesis techniques and software-based
prediction of epitopes, we found that many regions of
GRA4, particularly the regions represented by peptides
P2, P10 and P11, are involved in the pig antibody re-
sponse, and good reactivity with the T. gondii-infected
pig sera was observed. The identification of B cell epi-
topes is important for understanding antigenic structure
and parasite-antibody interactions at the molecular level
and may assist in the design of vaccines and diagnostic
reagents. The identification of B cell epitopes is an excit-
ing area of development. There are more linear and con-
formational B cell epitopes than previously predicted;
therefore, the number of identified epitopes should also
increase with additional studies.Competing interests
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